-

Monsanto Reacts to Decision on Post-Trial Motions in McKivison

Company Plans to Appeal Ruling

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, decisions on post-trial motions were handed down in the McKivison v. Monsanto litigation before Judge Susan Schulman in the Philadelphia Court of Common Pleas in reaction to the court’s decision on the Company’s post trial motion reducing the verdict to $400 million in total.

The original jury verdict reached on January 26, 2024, totaled $2.25 billion with $250 million in compensatory damages and $2 billion in punitive damages. The Company will seek an appeal from the Superior Court of Pennsylvania.

Monsanto issued the following statement:

“While the court’s decision reduces the unconstitutionally excessive damage award, we still disagree with the ruling on the liability verdict, as the trial was marred by significant and reversible errors that misled and inflamed the jury. There is no other explanation for the excessive damage awards. These errors reinforce the urgent need for legislative reform to clarify that compliance with labels required under federal law is sufficient to meet all state warning requirements. Otherwise, we risk more verdicts and excessive awards for a product that has consistently been found to be safe by regulatory bodies worldwide that will encumber funds that should be used for research and development to field new crop protection tools and help feed the world sustainably. By allowing this misapplication of the law to persist, our nation is needlessly driving up the cost of food and threatening its supply and innovation.

“It is clear that when trials focus on the science and regulatory consensus, the Company prevails as it has had favorable outcomes in 14 of the last 20 trials, including the last four, and has resolved the overwhelming majority of claims in this litigation.

“The Company stands behind Roundup™ and the overwhelming weight of scientific research and assessments by leading health regulators and scientists, including both the EPA and the EU, that support the safety of glyphosate-based products. No regulatory authority that has independently evaluated glyphosate has found it to be carcinogenic. Recently, the EU Commission re-approved glyphosate for 10 years, following the favorable scientific assessments by its health and safety agencies, including the European Chemicals Agency (ECHA) and European Food Safety Authority (EFSA), which ‘did not identify any critical areas of concern’ impacting public health or the environment in their review of glyphosate in July 2023.”

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims

ST. LOUIS--(BUSINESS WIRE)--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class. “We are pleased the Court granted preliminary approval of the class settlement, which is designed to resolve current and potential future Roundup claims relating to...

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose....
Back to Newsroom